A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent

This study has been completed.
Sponsor:
Information provided by:
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT00299026
First received: March 3, 2006
Last updated: August 28, 2008
Last verified: August 2008
  Purpose

The clinical investigation is an international, prospective, double-blind, randomized safety and efficacy study. The purpose of this study is to evaluate the safety and performance of the NIRx(TM) Paclitaxel-Coated Stent (1.0µg/mm2 of paclitaxel incorporated into slow- and moderate-release formulation of a triblock copolymer carrier system)in patients who present for stenting of de novo lesions of a native coronary artery.


Condition Intervention Phase
Coronary Artery Disease
Device: NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: TAXUS II: A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent

Resource links provided by NLM:


Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Mean percent in-stent net volume obstruction at 6 months post-procedure as measured by IVUS

Estimated Enrollment: 532
Study Start Date: June 2001
Study Completion Date: February 2007
Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)
Detailed Description:

The primary objective of this study is to evaluate the safety and performance of coronary artery stenting with the NIRx(TM) Paclitaxel-Coated Stent (1.0µg/mm2 of paclitaxel incorporated into slow- and moderate-release formulation of a triblock copolymer carrier system) for the treatment of de novo lesions in native vessels. Patients in 2 sequential cohorts will be randomised to receive either the NIRx(TM) Paclitaxel-Coated Stent or the uncoated control stent. In cohort 1, the slow-release formulation NIRx(TM) Paclitaxel-Coated Stent will be studied. If the safety profile is acceptable, the moderate-release formulation NIRx(TM) Paclitaxel-Coated Stent will be studied in Cohort 2. In each f the 2 cohorts, 133 patients will be treated with the NIRx(TM) paclitaxel-Coated Stent and 133 with the uncoated control stent (1.1 ratio), for a total of 532 patients in study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria:

  • Patient >= 18 years old.
  • Eligible for percutaneous transluminal coronary angioplasty (PTCA).
  • Patient (or legal guardian) understands the study requirements and the stent treatment procedure and provides written Informed Consent before any study-specific tests or procedures are performed.
  • Willing to comply with all specified follow-up evaluations.
  • Documented stable angina pectoris (Canadian Cardiovascular Society Classification [CCS] 1, 2, 3, or 4), unstable angina pectoris with documented ischemia (Braunwald Class IB - C, IIB - C, or IIIB - C), or documented silent ischemia.
  • Acceptable candidate for CABG.

Angiographic Inclusion Criteria:

  • Target lesion is located within a native coronary vessel.
  • Target lesion is de novo (i.e., a coronary lesion not previously treated).
  • Target lesion diameter stenosis >= 50% and <= 99% (visual estimate or on-line QCA).
  • Target lesion <= 12 mm in length (visual estimate or on-line QCA).
  • Target vessel >= 3.0 mm and <= 3.5 mm in diameter (visual estimate or on-line QCA).

General Exclusion Criteria:

  • Known sensitivity to paclitaxel.
  • Patient has received paclitaxel or other anti-mitogenic agent within 12 months prior to planned enrollment in the study.
  • Patient has previous stent procedure with any drug-coated or drug-eluting stent device.
  • Patient has undergone any coronary intervention within 30 days prior to stent placement associated with this protocol.
  • Patient anticipates planned additional intervention (staged procedure) to any non-target coronary vessel within 45 days after the stent placement associated with this protocol.
  • MI within 72 hours of planned stent placement.
  • Left ventricular ejection fraction (LVEF) of < 30%.
  • Stroke within the past 6 months.
  • Acute or chronic renal dysfunction (creatinine >1.7 mg/mL or >150 µmol/L).
  • Acetylsalicylic acid and/or clopidogrel and/or ticlopidine are contraindicated.
  • Leukopenia (leukocytes <3.5 x 109/liter).
  • Thrombocytopenia (platelets <100,000/mm3).
  • Active peptic ulcer or active gastrointestinal (GI) bleeding.
  • Known allergy to stainless steel.
  • Previously enrolled in the NIRx(TM) Coronary Stent Clinical Safety and Performance Study.
  • Currently enrolled in another investigational device or drug study and has not completed the required follow-up period, or has completed all other study-required follow-up less than 30 days prior to enrollment in this study.
  • Patient is lactating, has a positive pregnancy test within 7 days of planned stent placement, or intends to become pregnant during the study (only applies to female patients of child-bearing potential).
  • Life expectancy of less than 24 months because of other medical conditions.
  • Co-morbid condition(s) that could limit the patient's ability to participate in the study or comply with follow-up requirements or co-morbid condition(s) that could impact the scientific integrity of the study.

Angiographic Exclusion Criteria:

  • Unprotected left main coronary artery disease (or obstruction greater than 50% in the left main coronary artery that is not protected by at least 1 non-obstructed bypass graft to the left anterior descending [LAD] or circumflex artery or a branch thereof).
  • Target lesion is in a previously stented segment.
  • Target vessel was treated with directional coronary atherectomy, laser, or transluminal extraction catheter prior to stent placement.
  • Target lesion is ostial in location (within 3 mm of vessel origin).
  • Target site of stent placement has side branches >2.0 mm in diameter.
  • Target lesion is severely calcified (by visual estimate)
  • Target vessel has closed abruptly or is threatening closure.
  • Target lesion is located within or immediately distal to a >60° bend in the vessel.
  • Target vessel has diffuse disease requiring more than one 15 mm stent for full lesion coverage.
  • Target lesion involves a bifurcation where a branch vessel greater than 2.0 mm in diameter originates (either stenosis of both main vessel and major branch or stenosis of just major branch).
  • Target lesion has excessive tortuosity unsuitable for stent delivery and deployment.
  • Target lesion is located within a saphenous vein bypass graft.
  • Target lesion is located in a vessel section supplied by distal graft.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00299026

Locations
Italy
San Raffaele del Monte Tabor
Milano, Italy, 20132
Sponsors and Collaborators
Boston Scientific Corporation
Investigators
Principal Investigator: Antonio Colombo, MD Ospedale San Raffaele del Monte Tabor
  More Information

No publications provided by Boston Scientific Corporation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Thomas Naeschen, PhD, Boston Scientific
ClinicalTrials.gov Identifier: NCT00299026     History of Changes
Other Study ID Numbers: TAXUS II, S2003
Study First Received: March 3, 2006
Last Updated: August 28, 2008
Health Authority: Italy: National Institute of Health

Keywords provided by Boston Scientific Corporation:
Coronary Artery Disease
Percutaneous Coronary Intervention
Stent Implant
Drug-coated Stent

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Paclitaxel
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 23, 2014